A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
Latest Information Update: 12 Aug 2024
At a glance
- Drugs BGC 515 (Primary)
- Indications Haemangioendothelioma; Mesothelioma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors BridGene Biosciences
Most Recent Events
- 28 Jun 2024 According to a BridGene Biosciences media release, first patient has been dosed in this study. Dr. Timothy Yap, Ph.D., FRCP, Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) and Head of Clinical Development, Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, is the principal investigator at the initial US site, where the first patient has been enrolled.
- 17 Jun 2024 New trial record